electroCore Announces the Launch of Truvaga Plus® for General Wellness

2 years ago

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today…

Supernus Provides Regulatory Update for SPN-830

2 years ago

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

2 years ago

New advancements, including automation, aim to fast-forward spatial biologySOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools…

New Research From Inovalon and Harvard Analyzes Medicare Advantage Plan Design Impact on Healthcare Utilization and Health Equity

2 years ago

Latest Research Offers Policymakers and Health Plans Insights to Maximize and Tailor Benefits to Meet the Needs of Socioeconomically Disadvantaged…

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

2 years ago

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that…

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

2 years ago

Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of ActionDUBLIN, Ireland and BRIDGEWATER, N.J., April 08, 2024 (GLOBE NEWSWIRE) --…

Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting

2 years ago

CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company,…

MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES

2 years ago

Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today…

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

2 years ago

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca…